BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kumar S, Karuppanan K, Subramaniam G. Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment. J Med Virol 2022. [PMID: 35680610 DOI: 10.1002/jmv.27927] [Cited by in Crossref: 13] [Cited by in F6Publishing: 24] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Gerardi V, Rohaim MA, Naggar RFE, Atasoy MO, Munir M. Deep Structural Analysis of Myriads of Omicron Sub-Variants Revealed Hotspot for Vaccine Escape Immunity. Vaccines 2023;11:668. [DOI: 10.3390/vaccines11030668] [Reference Citation Analysis]
2 Lee Y, Liou C, Liu I, Chang J. T cell immunity of the nonadjuvanted HLA-restricted peptide COVID-19 vaccine.. [DOI: 10.21203/rs.3.rs-2119898/v1] [Reference Citation Analysis]
3 Fraser AJ, Greenland-Bews C, Kelly D, Williams CT, Body R, Adams ER, Atienzar AC, Edwards T, Allen DJ; LSTM Diagnostics Group, CONDOR Steering Group. A high-resolution melt curve toolkit to identify lineage-defining SARS-CoV-2 mutations. Sci Rep 2023;13:3887. [PMID: 36890186 DOI: 10.1038/s41598-023-30754-1] [Reference Citation Analysis]
4 Ford ES, Simmons W, Karmarkar EN, Yoke LH, Braimah AB, Orozco JJ, Ghiuzeli CM, Barnhill S, Sack CL, Benditt JO, Roychoudhury P, Greninger AL, Shapiro AE, Hammond JL, Rusnak JM, Dolsten M, Boeckh M, Liu C, Cheng GS, Corey L. Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir. Clin Infect Dis 2023;76:926-9. [PMID: 36326680 DOI: 10.1093/cid/ciac868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Milligan EC, Olstad K, Williams CA, Mallory M, Cano P, Cross KA, Munt JE, Garrido C, Lindesmith L, Watanabe J, Usachenko JL, Hopkins L, Immareddy R, Shaan Lakshmanappa Y, Elizaldi SR, Roh JW, Sammak RL, Pollard RE, Yee JL, Herbek S, Scobey T, Miehlke D, Fouda G, Ferrari G, Gao H, Shen X, Kozlowski PA, Montefiori D, Hudgens MG, Edwards DK, Carfi A, Corbett KS, Graham BS, Fox CB, Tomai M, Iyer SS, Baric R, Reader R, Dittmer DP, Van Rompay KKA, Permar SR, De Paris K. Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge 1 year later. Sci Transl Med 2023;15:eadd6383. [PMID: 36454813 DOI: 10.1126/scitranslmed.add6383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Das NC, Chakraborty P, Bayry J, Mukherjee S. Comparative Binding Ability of Human Monoclonal Antibodies against Omicron Variants of SARS-CoV-2: An In Silico Investigation. Antibodies 2023;12:17. [DOI: 10.3390/antib12010017] [Reference Citation Analysis]
7 Teli D, Balar P, Patel K, Sharma A, Chavda V, Vora L. Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants. Metabolites 2023;13. [PMID: 36837928 DOI: 10.3390/metabo13020309] [Reference Citation Analysis]
8 Lee M, Major M, Hong H. Distinct Conformations of SARS-CoV-2 Omicron Spike Protein and Its Interaction with ACE2 and Antibody. Int J Mol Sci 2023;24. [PMID: 36835186 DOI: 10.3390/ijms24043774] [Reference Citation Analysis]
9 Singh J, Anantharaj A, Panwar A, Rani C, Bhardwaj M, Kumar P, Chattopadhyay P, Devi P, Maurya R, Mishra P, Pandey AK, Pandey R, Medigeshi GR. BA.1, BA.2 and BA.2.75 variants show comparable replication kinetics, reduced impact on epithelial barrier and elicit cross-neutralizing antibodies. PLoS Pathog 2023;19:e1011196. [PMID: 36827451 DOI: 10.1371/journal.ppat.1011196] [Reference Citation Analysis]
10 Mao S, Li S, Zhang Y, Long L, Peng J, Cao Y, Mao JZ, Qi X, Xin Q, San G, Ding J, Jiang J, Bai X, Wang Q, Xu P, Xia H, Lu L, Xie L, Kong D, Zhu S, Xu W. A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2. Nano Today 2023;48:101730. [PMID: 36570700 DOI: 10.1016/j.nantod.2022.101730] [Reference Citation Analysis]
11 Khan MS, Kim E, Huang S, Kenniston TW, Gambotto A. Trivalent SARS-CoV-2 S1 Subunit Protein Vaccination Induces Broad Humoral Responses in BALB/c Mice. Vaccines (Basel) 2023;11. [PMID: 36851191 DOI: 10.3390/vaccines11020314] [Reference Citation Analysis]
12 Kumar R, Reji M. Emergence of SARS-CoV-2 variant of concern omicron: biological features and genomic concern. IJMR 2023;9:252-271. [DOI: 10.18231/j.ijmr.2022.044] [Reference Citation Analysis]
13 Favaro M, Zampini P, Pistoia ES, Gaziano R, Grelli S, Fontana C. Rapid System to Detect Variants of SARS-CoV-2 in Nasopharyngeal Swabs. Viruses 2023;15. [PMID: 36851567 DOI: 10.3390/v15020353] [Reference Citation Analysis]
14 Chatterjee S, Bhattacharya M, Nag S, Dhama K, Chakraborty C. A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies. Viruses 2023;15. [PMID: 36680207 DOI: 10.3390/v15010167] [Reference Citation Analysis]
15 Chakraborti S, Gill J, Goswami R, Kumar S, Chandele A, Sharma A. Structural Profiles of SARS-CoV-2 Variants in India. Curr Microbiol 2022;80:1. [PMID: 36414797 DOI: 10.1007/s00284-022-03094-y] [Reference Citation Analysis]
16 Singh JK, Dubey S, Srivastava G, Siddiqi MI, Srivastava SK. Neohesperidin and spike RBD interaction in omicron and its sub-variants: In silico, structural and simulation studies. Comput Biol Med 2023;152:106392. [PMID: 36502697 DOI: 10.1016/j.compbiomed.2022.106392] [Reference Citation Analysis]
17 Ahmadi K, Shahbazi B, Zakeri AJ, Gouklani H. Characterization of SARS-CoV-2 omicron variants from Iran and evaluation of the effect of mutations on the spike, nucleocapsid, ORF8, and ORF9b proteins function. J Biomol Struct Dyn 2022;:1-16. [PMID: 36576175 DOI: 10.1080/07391102.2022.2162131] [Reference Citation Analysis]
18 Ward T, Glaser A, Overton CE, Carpenter B, Gent N, Seale AC. Replacement dynamics and the pathogenesis of the Alpha, Delta and Omicron variants of SARS-CoV-2. Epidemiol Infect 2022;151:e32. [PMID: 36535802 DOI: 10.1017/S0950268822001935] [Reference Citation Analysis]
19 Boschi C, Scheim DE, Bancod A, Militello M, Bideau ML, Colson P, Fantini J, Scola B. SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects. Int J Mol Sci 2022;23. [PMID: 36555121 DOI: 10.3390/ijms232415480] [Reference Citation Analysis]
20 Ramadan Abdelmoez Farahat, Abdelaziz Abdelaal, Tungki Pratama Umar, Amro A. El-Sakka, Amira Yasmine Benmelouka, Khaled Albakri, Iftikhar Ali, Tareq Al-Ahdal, Basel Abdelazeem, Ranjit Sah, Alfonso J. Rodriguez-Morales. The emergence of SARS-CoV-2 Omicron subvariants: current situation and future trends. Infez Med 2022;30. [PMID: 36482957 DOI: 10.53854/liim-3004-2] [Reference Citation Analysis]
21 Kobusiak-Prokopowicz M, Fułek K, Fułek M, Kaaz K, Mysiak A, Kurpas D, Beszłej JA, Brzecka A, Leszek J. Cardiovascular, Pulmonary, and Neuropsychiatric Short- and Long-Term Complications of COVID-19. Cells 2022;11. [PMID: 36497138 DOI: 10.3390/cells11233882] [Reference Citation Analysis]
22 Boschi C, Scheim DE, Bancod A, Millitello M, Bideau ML, Colson P, Fantini J, Scola BL. SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects.. [DOI: 10.1101/2022.11.24.517882] [Reference Citation Analysis]
23 Ntziora F, Kostaki EG, Karapanou A, Mylona M, Tseti I, Sipsas NV, Paraskevis D, Sfikakis PP. Protection of vaccination versus hybrid immunity against infection with COVID-19 Omicron variants among Health-Care Workers. Vaccine 2022;40:7195-200. [PMID: 36150972 DOI: 10.1016/j.vaccine.2022.09.042] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
24 Roohani J, Keikha M. Global challenge with the SARS-CoV-2 omicron BA.2 (B.1.1.529.2) subvariant: Should we be concerned? World J Virol 2022; 11(6): 496-501 [DOI: 10.5501/wjv.v11.i6.496] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Miyauchi S, Hiyama T, Nakano Y, Yoshino A, Miyake Y, Okamoto Y. Is a booster dose of COVID-19 vaccines effective on newly dominant omicron subvariants among university students? Comparison between BA.1 and BA.2 dominancy. Am J Infect Control 2022:S0196-6553(22)00813-6. [PMID: 36435404 DOI: 10.1016/j.ajic.2022.11.015] [Reference Citation Analysis]
26 Panda M, Kalita E, Singh S, Kumar K, Prajapati VK. Nanobody-peptide-conjugate (NPC) for passive immunotherapy against SARS-CoV-2 variants of concern (VoC): a prospective pan-coronavirus therapeutics. Mol Divers 2022. [DOI: 10.1007/s11030-022-10570-x] [Reference Citation Analysis]
27 Aralis Z, Comer S, Ansorg H, Palmer C, Smith J, Feinstein SC, Fitzgibbons LN, Arias C. Efficient Tracing of the SARS-CoV-2 Omicron Variants in Santa Barbara County Using a Rapid Quantitative Reverse Transcription PCR Assay. Diagnostics (Basel) 2022;12. [PMID: 36428863 DOI: 10.3390/diagnostics12112805] [Reference Citation Analysis]
28 Sharma P, Kumar M, Tripathi MK, Gupta D, Vishwakarma P, Das U, Kaur P. Genomic and structural mechanistic insight to reveal the differential infectivity of omicron and other variants of concern. Computers in Biology and Medicine 2022;150:106129. [DOI: 10.1016/j.compbiomed.2022.106129] [Reference Citation Analysis]
29 Chakraborty C, Bhattacharya M, Sharma AR, Dhama K, Lee S. The rapid emergence of multiple sublineages of Omicron (B.1.1.529) variant: Dynamic profiling via molecular phylogenetics and mutational landscape studies. Journal of Infection and Public Health 2022;15:1234-1258. [DOI: 10.1016/j.jiph.2022.10.004] [Reference Citation Analysis]
30 Dong Hoon Shin, Davey M. Smith, Jun Yong Choi. SARS-CoV-2 Omicron Variant of Concern: Everything You Wanted to Know about Omicron but Were Afraid to Ask. Yonsei Med J 2022;63. [PMID: 36303305 DOI: 10.3349/ymj.2022.0383] [Reference Citation Analysis]
31 Jäger M, Dichtl S, Bellmann-Weiler R, Reindl M, Lass-Flörl C, Wilflingseder D, Posch W. Serum Neutralization Against SARS-CoV-2 Variants Is Heterogenic and Depends on Vaccination Regimen. J Infect Dis 2023;227:528-32. [PMID: 36315869 DOI: 10.1093/infdis/jiac432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Zhao J, Zhu J, Huang C, Zhu X, Zhu Z, Wu Q, Yuan R. Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1035151] [Reference Citation Analysis]
33 Tauzin A, Gong SY, Chatterjee D, Ding S, Painter MM, Goel RR, Beaudoin-Bussières G, Marchitto L, Boutin M, Laumaea A, Okeny J, Gendron-Lepage G, Bourassa C, Medjahed H, Goyette G, Williams JC, Bo Y, Gokool L, Morrisseau C, Arlotto P, Bazin R, Fafard J, Tremblay C, Kaufmann DE, De Serres G, Richard J, Côté M, Duerr R, Martel-Laferrière V, Greenplate AR, Wherry EJ, Finzi A. A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses. Cell Rep 2022;41:111554. [PMID: 36244343 DOI: 10.1016/j.celrep.2022.111554] [Reference Citation Analysis]
34 Rahman S, Hossain MJ, Nahar Z, Shahriar M, Bhuiyan MA, Islam MR. Emerging SARS-CoV-2 Variants and Subvariants: Challenges and Opportunities in the Context of COVID-19 Pandemic. Environ Health Insights 2022;16:11786302221129396. [PMID: 36299441 DOI: 10.1177/11786302221129396] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Hassan HA, Hassan AR, Mohamed EAR, Al-Khdhairawi A, Taha HE, El-Tantawy HM, Abdel-Rahman IAM, Raslan AE, Allemailem KS, Almatroudi A, Alrumaihi F, Alshiekheid MA, Rehman HM, Abdelhamid MM, Abdel-Rahman IM, Allam AE. Targeting Natural Plant Metabolites for Hunting SARS-CoV-2 Omicron BA.1 Variant Inhibitors: Extraction, Molecular Docking, Molecular Dynamics, and Physicochemical Properties Study. Curr Issues Mol Biol 2022;44:5028-47. [PMID: 36286057 DOI: 10.3390/cimb44100342] [Reference Citation Analysis]
36 Tulimilli SV, Dallavalasa S, Basavaraju CG, Kumar Rao V, Chikkahonnaiah P, Madhunapantula SV, Veeranna RP. Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. Vaccines (Basel) 2022;10. [PMID: 36298616 DOI: 10.3390/vaccines10101751] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Chavda VP, Yao Q, Vora LK, Apostolopoulos V, Patel CA, Bezbaruah R, Patel AB, Chen Z. Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world. Front Immunol 2022;13:961198. [DOI: 10.3389/fimmu.2022.961198] [Reference Citation Analysis]
38 Pitsillou E, Liang JJ, Beh RC, Hung A, Karagiannis TC. Molecular dynamics simulations highlight the altered binding landscape at the spike-ACE2 interface between the Delta and Omicron variants compared to the SARS-CoV-2 original strain. Computers in Biology and Medicine 2022;149:106035. [DOI: 10.1016/j.compbiomed.2022.106035] [Reference Citation Analysis]
39 Shaheen N, Mohamed A, Attalla A, Diab RA, Swed S, Nashwan AJ, Rababah AA, Hefnawy MT, Soliman Y, Abdelwahab OA, Desouki MT, Khaity A, Shaheen A, Ramadan A, Meshref M. Could the New BA.2.75 Sub-Variant Cause the Emergence of a Global Epidemic of COVID-19? A Scoping Review. IDR 2022;Volume 15:6317-6330. [DOI: 10.2147/idr.s387551] [Reference Citation Analysis]
40 Feng XL, Yu D, Zhang M, Li X, Zou QC, Ma W, Han JB, Xu L, Yang C, Qu W, Deng ZH, Long J, Long Y, Li M, Yao YG, Dong XQ, Zeng J, Li MH. Characteristics of replication and pathogenicity of SARS-CoV-2 Alpha and Delta isolates. Virol Sin 2022;37:804-12. [PMID: 36167254 DOI: 10.1016/j.virs.2022.09.007] [Reference Citation Analysis]
41 Rana R, Kant R, Huirem RS, Bohra D, Ganguly NK. Omicron variant: Current insights and future directions. Microbiol Res 2022;265:127204. [PMID: 36152612 DOI: 10.1016/j.micres.2022.127204] [Reference Citation Analysis]
42 Berno G, Fabeni L, Matusali G, Gruber CEM, Rueca M, Giombini E, Garbuglia AR. SARS-CoV-2 Variants Identification: Overview of Molecular Existing Methods. Pathogens 2022;11:1058. [PMID: 36145490 DOI: 10.3390/pathogens11091058] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Yamacli S, Avci M. Computation of the Binding Energies between Human ACE2 and Spike RBDs of the Original Strain, Delta and Omicron Variants of the SARS‐CoV‐2: A DFT Simulation Approach. Advcd Theory and Sims. [DOI: 10.1002/adts.202200337] [Reference Citation Analysis]
44 Barozi V, Edkins AL, Tastan Bishop Ö. Evolutionary progression of collective mutations in Omicron sub-lineages towards efficient RBD-hACE2: Allosteric communications between and within viral and human proteins. Comput Struct Biotechnol J 2022;20:4562-78. [PMID: 35989699 DOI: 10.1016/j.csbj.2022.08.015] [Reference Citation Analysis]
45 Chaudhari AM, Joshi M, Kumar D, Patel A, Lokhande KB, Krishnan A, Hanack K, Filipek S, Liepmann D, Renugopalakrishnan V, Paulmurugan R, Joshi C. Evaluation of immune evasion in SARS-CoV-2 Delta and Omicron variants. Comput Struct Biotechnol J 2022;20:4501-16. [PMID: 35965661 DOI: 10.1016/j.csbj.2022.08.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Dhawan M, Saied AA, Mitra S, Alhumaydhi FA, Emran TB, Wilairatana P. Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2? Biomed Pharmacother 2022;154:113522. [PMID: 36030585 DOI: 10.1016/j.biopha.2022.113522] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
47 Rahimi F, Talebi Bezmin Abadi A. Implications of the SARS-CoV-2 subvariants BA.4 and BA.5. Int J Surg 2022;104:106806. [PMID: 35926828 DOI: 10.1016/j.ijsu.2022.106806] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Mengist HM, Kombe Kombe JA, Jin T. Immune Evasion by the Highly Mutated SARS-CoV-2 Omicron Variant. IDR 2022;Volume 15:4013-27. [DOI: 10.2147/idr.s366437] [Reference Citation Analysis]
49 Tiecco G, Storti S, Arsuffi S, Degli Antoni M, Focà E, Castelli F, Quiros-roldan E. Omicron BA.2 Lineage, the “Stealth” Variant: Is It Truly a Silent Epidemic? A Literature Review. IJMS 2022;23:7315. [DOI: 10.3390/ijms23137315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Grüne B, Grüne J, Kossow A, Joisten C. Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron). Vaccines (Basel) 2022;10. [PMID: 35891167 DOI: 10.3390/vaccines10071003] [Reference Citation Analysis]
51 Celik I, Abdellattif MH, Tallei TE. An Insight Based on Computational Analysis of the Interaction between the Receptor-Binding Domain of the Omicron Variants and Human Angiotensin-Converting Enzyme 2. Biology (Basel) 2022;11:797. [PMID: 35625526 DOI: 10.3390/biology11050797] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]